Interventional, randomised, double-blind, parallel-group study of the efficacy and safety of initial administration of 17 mg vortioxetine intravenously with 10 mg/day vortioxetine orally in patients with Major Depressive Disorder
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2017
At a glance
- Drugs Vortioxetine (Primary) ; Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Lundbeck A/S
- 05 Jul 2017 Status changed from active, no longer recruiting to completed.
- 02 Jun 2017 This trial has been completed in Estonia (end date: 2017-04-27), according to European Clinical Trials Database.
- 26 May 2017 This trial was completed in Finland (end date: 2017-04-27), according to European Clinical Trials Database.